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Introduction: Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by self-limited
recurrent attacks of fever and serositis. Patients may develop renal amyloidosis. Colchicine prevents attacks and
renal amyloidosis. Five to 10 % of the patients with FMF are resistant or intolerant to colchicine.
Case description: Herein, we reported our experience with clinical-laboratory features and treatment responses of
a pediatric FMF patient with amyloidosis treated with canakinumab. We observed a significant decrease in proteinuria
and increase growth in the patient.
Discussion and evaluation: The most serious complication of FMF is the development of AA type amyloidosis which
is characterized by proteinuria. Colchicine is the prototype drug that decreases production of amyloidogenic precursor
protein. Occasionally, colchicine inadequate patient is observed, as in our case. Canakinumab is a human anti-IL-1β
monoclonal antibody. Previously, canakinumab efficacy were shown in a limited number of studies.
Conclusions: Our data, though limited to only one patient, emphasize that therapeutic intervention with canakinumab
seems to be improve kidney function in colchicine-resistant FMF with renal amyloidosis.
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Familial Mediterranean fever (FMF) is a genetic, auto-
inflammatory disease, characterized by acute episodes
of serosal and cutaneous inflammation, expressed with
pain, fever, neutrophilia, and intense acute-phase re-
sponse, caused by activation of the innate immune
system [1]. The FMF gene, named MEFV, is located
on the short arm of chromosome 16 [2, 3]. It encodes
a 781–amino acid protein called pyrin or marenostrin
which is expressed mostly in neutrophils and acts in
controlling inflammation by deactivating inflammatory
peptides [4, 5]. Mutated forms of it may be involved
in a series of reactions that ultimately enhance the
overexpression of IL-1b and consequent inflammation [1].
FMF has been associated with an increased risk for
secondary amyloidosis, mainly affecting the renal and* Correspondence: betulsozeri@yahoo.com
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patients with FMF. Amyloidosis is a progressive destruc-
tive disorder that results in organ dysfunction due to
extracellular deposition of N terminal fragments of
serum amyloid A protein (SAA) in the form of insoluble
amyloid fibrils [6]. Proteinuria is usually the earliest and
most common clinical manifestation of AA amyloidosis
in patients with inflammatory diseases [6].
The goal of therapy for FMF is the prevention of acute
attacks, development, and progression of amyloidosis.
Colchicine is the mainstay of therapy which decreases
attack frequency and increases the quality of life in more
than 60 % of patients [7]. It also prevents SAA secretion
and slows the progression of amyloidosis in patients
with FMF [7]. Approximately 40 % of FMF patients
treated with colchicine have a partial remission
showed in the Eurofever study [8]. Also, 5–10 % of
the patients were reported to be resistant; suffering
from either more than six typical FMF attacks per
year or more than three typical FMF attacks withinis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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tients with FMF were successfully treated with agents
blocking interleukin (IL)-1 activity due to the critical
role of IL-1 in the pathogenesis FMF [10–14].
Canakinumab is a high-affinity human anti-IL1 β mono-
clonal antibody of the IgG1/k isotype developed for the treat-
ment of immune disorders, and it is highly specific for IL-1β
and does not interfere with other IL-1-activated pathways.
We would like to share our experience of a patient with
colchicine-resistant FMF and renal amyloidosis, whose treat-
ment with canakinumab substantially improved renal func-
tions and reduced proteinuria over a period of 26 months.
Case presentation
A 14-year-old male with colchicine-resistant FMF and
amyloidosis was admitted for the first time in May 2013.
He was born to parents of second-degree consanguineous
marriage. He had taken regular colchicine therapy (2 g/
day) and ramipril (5 mg/day) for proteinuria for a year.
From his history, he had recurrent FMF attacks associ-
ated with severe abdominal pain, joint pain, and fever,
which had begun at the age of four. However, he was hos-
pitalized for the first time at the age of 7 years because of
intermittent febrile episodes with chills, abdominal pain,
and arthritis involving ankle joints. Splenomegaly was
found a year later. His attacks continued once a month
until he was diagnosed with FMF at 13 years old. At that
time, he had proteinuria, splenomegaly, and growth retard-
ation. He was homozygous for the M694V mutation in
MEFV gene. Also, microhematuria and proteinuria
(38 mg/m2/h) was found at his urinalysis. Serum creatinine
level was 1.1 mg/dl, and creatinine clearance was 89 mL/
min. Diagnosis of chronic kidney disease (CKD) with AAFig. 1 Renal amyloid deposition was diagnosed in glomerulus by two diffeamyloidosis was established via renal biopsy (Fig. 1). Severe
glomerular amyloidosis plus mild vascular and mild inter-
stitial amyloidosis was found in his kidney biopsy. Colchi-
cine therapy was started with a dose of 1 mg/day. In the
first month of treatment, he was clinically normal and his
C-reactive protein (CRP) level was within normal limits. At
his 6-month follow up, the dose of colchicine had to be in-
creased (2 g/day) due to an increased attack rate (5 attacks
per 6 months) despite the regular use of drugs.
The laboratory findings on admission revealed an ele-
vated CRP (184 mg/dL) and SAA (645 mg/dL) levels.
Nephrotic range proteinuria was found in urine analysis
(43 mg/m2/h). Because of his poor response to colchicine,
severe growth retardation, and severe proteinuria due to
amyloidosis, we decided to start canakinumab treatment
(150 mg/month/sc) in June 2013. Informed consent about
the potential side effects and the empirical aspects of the
therapy was obtained. One month later, the patient was
symptom-free and the inflammatory parameters almost
normalized. After 26 months of follow-up, with canakinu-
mab treatment, his complaints, inflammatory parameters
(CRP; 0.03 mg/dl and SAA; 3.81 mg/dl) and proteinuria
were decreased. Splenomegaly was decreased and also his
growth rate returned to normal (Fig. 2), after canakinumab
therapy. The mean height SDS before therapy was sig-
nificantly lower than after canakinumab (−2.12 ± 0,11
vs −1.71 ± 0,14, P = 0,009) (Fig. 3). He was kept on
2 mg of colchicine daily. No side effects were noted.
Discussion and evaluation
The most serious complication of FMF is the develop-
ment of AA type amyloidosis which is characterized by
proteinuria and is typically progressive and leads to end-rent staining
Fig. 2 Effect of canakinumab on proteinuria (miligrams/m2(per hour)
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and Cattan in 1952 [15]. Renal amyloidosis has been
shown to cause mortality in FMF patients [16]. In the
series reported by the Turkish FMF study group, the
presenting clinical features of the patients with amyloid-
osis secondary to FMF were as follows: 32 % proteinuria,
40 % nephrotic syndrome, and 28 % chronic renal failure
[17]. The M694V mutation has been shown to be a
strong risk factor of developing amyloidosis in different
ethnic groups [17]. The production of the precursor to
SAA is the main step in the pathogenesis of amyloidosis,
which is produced by inflammatory signals, IL-1β, tumor
necrosis factor (TNF)-α, and IL-6 [18]. The “gold
standard” for the diagnosis of amyloidosis remains a
tissue biopsy demonstrating characteristic hematoxylin
and eosin changes and Congo red birefringence or
metachromatic pink-violet staining with methyl violet
or crystal violet [19]. The patient’s renal biopsy was
evaluated with the scoring system defined for renal
amyloidosis and was found as severe glomerular amyl-
oidosis plus mild vascular and mild interstitial amyl-
oidosis. The scoring system proposed by Sen S et al.
[20] in 2010 and compared to clinical parameters by
Castano et al. [21]. They have demonstrated that the
severity of glomerular amyloid deposition was corre-
lated the risk of developing end-stage renal disease
and increase the risk for premature death [21]. Also
they have reported proteinuria, and serum albuminFig. 3 Effect of canakinumab on growth parameters (height and weight)and serum creatinine levels were correlated with degree of
amyloidosis [21]. Also, the degree of amyloidosis was mea-
sured through parameters such as SAA protein and serum
amyloid P (SAP) scintigraphy [18, 22].
Herein, we reported a FMF patient with biopsy-proven
renal amyloidosis and growth retardation. He had vari-
ous risk factors for amyloidosis including carrying the
M694V allele, family history, and late diagnosis.
Pro-inflammatory cytokines may modulate growth pat-
terns in children with inflammatory diseases through both
systemic and local effects of the GH/IGF-1 axes [23]. It
has been shown that FMF patients catch up to their
growth with an effective colchicine treatment [24–26].
The aim of treatment in AA amyloidosis is the sup-
pression, as complete as possible, of the inflammatory
process responsible for the overwhelming SAA produc-
tion. Colchicine is the prototype drug that decreases
production of amyloidogenic precursor protein. Occa-
sionally, colchicine inadequate patient is observed, as in
our case. In such circumstances, anti IL-1 treatment op-
tions come into play. Anti- IL-1 drugs impact on amyl-
oidosis is still unknown. Previously, there were reports
of some adult cases with successful use of anti IL-1 ther-
apy (anakinra) in renal transplant recipients [11, 12].
There are few data from pediatric patients in literature.
Bilginer Y et al. [27] reported a patient who was diag-
nosed with FMF and Behçet’s disease and proteinuria,
with normal kidney function after 18 months of anakinra
treatment. Recently, Ozcakar et al. [28] showed one
child patient with nephrotic syndrome in whom partial
remission had been observed after 12 months of ana-
kinra therapy.
Canakinumab is a human anti-IL-1β monoclonal anti-
body. Its mode of action is based on the neutralization
of IL-1β signaling which may result in the suppression
of the inflammation process. To the best of our know-
ledge, about de novo canakinumab treatment in FMF
patients with AA amyloidosis is limited. Topaloglu R
et al. [29] reported a patient diagnosed amyloidosis was
successful treated with canakinumab.
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adult and pediatric FMF colchicine-resistant patients
who were treated with anti-IL-1 agents. Twelve patients
were receiving anakinra, and eight patients were treated
with canakinumab. The number of monthly and yearly at-
tacks after IL-1 treatment significantly decreased after the
biologic agent (p < 0.05). Hashkes P et al. [13] conducted
an open-label, single-arm study in seven children with
colchicine-resistant FMF. Six participants met the primary
outcome with ≥50 % reduction (range 76–100 %) in the
FMF attack rate. The median 28-day time-adjusted attack
rate decreased from 2.7 to 0.3 (89 %). Canakinumab was
shown to be effective in treating pediatric patients with
colchicine-resistant FMF in this study. Another study re-
ported that in children with colchicine-resistant FMF,
monthly canakinumab 150 mg subcutaneous injections
prevented FMF attacks in patients with frequent attacks,
and only one of nine patients experienced an attack dur-
ing the treatment period [14].
Conclusions
Canakinumab has demonstrated a sustained clinical re-
sponse in the patient affected by colchicine-resistant
FMF and biopsy-proven renal amyloid deposits, blocking
and significantly reducing renal damage progression.
Also, we observed the normalization of the markers of
inflammation inc. SAA, and the reduction of proteinuria
in an overall period. Moreover, his growth pattern was
improved with therapy. No adverse events, namely infec-
tious episodes, were reported in our patient during treat-
ment with canakinumab. We did not consider making a
repeat biopsy for proteinuria completely regressed.
Our report emphasizes that the therapeutic interven-
tion with canakinumab can treat colchicine-resistant
FMF by suppressing inflammation and to prevent its
most life-threatening complication, amyloidosis-related
proteinuria. Further evaluations are needed in order to
confirm the positive effect of canakinumab.
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